
Is EDSA (Edesa Biotech, Inc.) Halal or Haram?
Edesa Biotech comfortably passes all AAOIFI financial screens, making it a fully shariah-compliant investment. The company operates entirely debt-free with a 0.0% debt-to-market cap ratio, and its cash reserves sit comfortably at 14.6% of market capitalization. Furthermore, it generates zero interest income, ensuring its revenues remain pure from an Islamic finance perspective.
Price Chart (5D)
EDSA — Last 7 Days
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 2026-06-08 | 5.74 | 5.84 | 4.94 | 5.37 | 303K | -6.45% |
| 2026-06-05 | 7.61 | 7.61 | 5.01 | 5.46 | 765K | -28.25% |
| 2026-06-04 | 6.80 | 7.45 | 6.69 | 7.09 | 145K | +4.26% |
| 2026-06-03 | 6.78 | 7.09 | 6.51 | 6.86 | 150K | +1.18% |
| 2026-06-02 | 6.75 | 7.78 | 6.73 | 6.83 | 237K | +1.19% |
| 2026-06-01 | 7.05 | 7.05 | 6.49 | 6.69 | 364K | -5.11% |
| 2026-05-29 | 7.75 | 7.79 | 7.19 | 7.22 | 247K | -6.84% |
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for EDSA
Business Activity
Permissible
Edesa Biotech passes the business activity screen as its core operations of developing clinical-stage treatments like EB05 for ARDS and EB01 for dermatitis are permissible healthcare activities.
Debt / Market Cap
0.00%
Interest Income
0.00%
Cash & Securities
14.60%
About Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for inflammatory and immune-related diseases. Its lead product candidates include EB05, a monoclonal antibody in Phase 3 trials for acute respiratory distress syndrome, and EB01, a topical treatment for chronic allergic contact dermatitis.
For Muslim investors, EDSA represents a clear Halal investment opportunity within the biotechnology sector. The stock successfully passes all four AAOIFI shariah screens, meaning its core healthcare operations and financial structures align completely with Islamic principles.
From an Islamic finance perspective, Edesa Biotech's balance sheet is exceptionally clean. The company currently carries no interest-bearing debt (0.0% against market cap) and generates no impermissible interest income, providing peace of mind for halal portfolio builders. Its cash and securities ratio of 14.6% also remains safely below the 33% maximum limit.
Since biotechnology firms often rely on future licensing deals or capital raises to fund ongoing clinical trials, Muslim investors should periodically monitor EDSA's balance sheet. Any future conventional debt financing could alter its current zero-debt status and affect its shariah compliance.
CEO
Pardeep Nijhawan
Employees
16
IPO Date
2010-06-21
Headquarters
Markham, ON, CA
Website
www.edesabiotech.comEDSA Key Financial Statistics
Revenue
$0
Net Income
$-7.2M
EPS (Diluted)
$-1.27
Stock Price
8.86
Beta
-0.68
52-Week Range
0.72-9.6341
Total Debt
$0
Total Equity
$12.5M
Current Ratio
10.67
EDSA Financial Health & Profitability
Profit Margins
Net Cash
$10.8M
Cash: $10.8M — Debt: $0
R&D Spending
$3.7M
% of Revenue
0%
Frequently Asked Questions About EDSA
Is EDSA (Edesa Biotech, Inc.) stock halal to invest in?▾
What does Edesa Biotech, Inc. do?▾
What screening criteria were used for EDSA?▾
Does EDSA require income purification?▾
When was EDSA last screened?▾
Disclaimer
This shariah compliance assessment for EDSA (Edesa Biotech, Inc.) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-27.